Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis)
Latest Information Update: 15 Feb 2024
At a glance
- Drugs Siponimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 09 Feb 2024 Status changed from recruiting to completed.
- 28 Oct 2021 Planned End Date changed from 31 Jan 2026 to 28 Feb 2025.
- 28 Oct 2021 Planned primary completion date changed from 31 Jan 2026 to 28 Feb 2025.